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To determine uptake of home sampling kit (HSK) for STI/HIV compared to clinic-based test-
ing, whether the availability of HSK would increase STI testing rates amongst HIV infected
MSM, and those attending a community-based HIV testing clinic compared to historical con-
trol. Prospective observational study in three facilities providing STI/HIV testing services in
Brighton, UK was conducted. Adult MSM attending/contacting a GUM clinic requesting an
STI screen (group 1), HIV infected MSM attending routine outpatient clinic (group 2), and
MSM attending a community-based rapid HIV testing service (group 3) were eligible. Partici-
pants were required to have no symptomatology consistent with STI and known to be im-
mune to hepatitis A and B (group 1). Eligible men were offered a HSK to obtain self-collected
specimens as an alternative to routine testing. HSK uptake compared to conventional clinic-
based STI/HIV testing in group 1, increase in STI testing rates due to availability of HSK com-
pared to historical controls in group 2 and 3, and HSK return rates in all settings were calculat-
ed. Among the 128 eligible men in group 1, HSK acceptance was higher (62.5% (95%CI:
53.5–70.9)) compared to GUM clinic-based testing (37.5% (95%CI: 29.1–46.5)), (p =
0.0004). Two thirds of eligible MSM offered an HSK in all three groups accepted it, but HSK
return rates varied (highest in group 1, 77.5%, lowest in group 3, 16%). HSK for HIV testing
was acceptable to 81% of men in group 1. Compared to historical controls, availability of HSK
increased the proportion of MSM testing for STIs in group 2 but not in group 3. HSK for STI/
HIV offers an alternative to conventional clinic-based testing for MSM seeking STI screening.
It significantly increases STI testing uptake in HIV infected MSM. HSK could be considered
as an adjunct to clinic-based services to further improve STI/HIV testing in MSM.
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Introduction
In the UK men who have sex with men (MSM) are disproportionately affected with HIV and
sexually transmitted infections (STI). The rates of STIs and HIV among MSM are increasing,
and the uptake of STI and HIV testing in conventional clinical settings is suboptimal [1]. The
prevalence of undiagnosed HIV and late HIV diagnosis among MSM continues to be high
[1,2]. The introduction of national targets for improved access to Genitourinary Medicine
(GUM) services [3] has increased the availability of testing in the clinical environment [4]. Na-
tional HIV testing guidance and community-based organisations have increasingly advocated
the broadening of STI/HIV testing to non-clinical sites to increase HIV testing uptake and re-
duce the burden of undiagnosed HIV [5,6]. There is a need to develop novel approaches to in-
crease HIV testing amongst MSM. Furthermore, since it is well established that the presence of
STI facilitates HIV transmission and acquisition [7–9] there is a need to optimise STI testing in
MSM.
Home sampling/testing may be one such initiative to meet these national aims. As part of
England’s National Chlamydia Screening Programme (NCSP) self sampling has been widely
used to test for Chlamydia trachomatis (CT). This programme has primarily targeted females,
and almost exclusively a heterosexual population [10]. Our research group has confirmed that
home sampling is an acceptable alternative to conventional testing in MSM [11,12], rectal and
oropharyngeal self-sampling is acceptable and feasible [13], and performs as well as conven-
tional nurse-taken diagnostic sampling [14].
The objectives of this study were to determine uptake of home sampling for HIV and STIs
compared to conventional clinic-based testing, and to determine whether the availability of
home sampling would increase STI testing amongst HIV infected MSM and those attending a
community-based HIV testing service compared to historical controls. We hypothesised that
the uptake of home sampling for sexual health screening would be higher compared to conven-
tional testing among asymptomatic MSM accessing a GUM clinic. We also hypothesised that
offering home sampling for STI testing to HIV positive MSM attending an HIV outpatient




The study was a prospective observational study evaluating the uptake of home sampling for
STI/HIV, and examine whether the availability of home sampling would increase STI testing
rates amongst HIV infected MSM and those attending a community-based HIV testing clinic
compared to a historical control (i.e. the comparator was testing rates in the corresponding cal-
endar period in the previous year).
Participants
The study was conducted between February and September 2008 in three sites providing STI
and/or HIV testing services in Brighton, UK. Eligible individuals were HIV negative (by self–
report) MSM attending in person or contacting the GUM clinic via telephone requesting an
STI screen (group 1), MSM with HIV infection attending the HIV outpatient clinic for routine
outpatient follow-up (group 2), and MSM attending a rapid HIV testing service provided by
the GUM clinic in a community-based organisation and (group 3). Participants were required
to have no symptomatology consistent with STI, be 18 years or over, and were known to be im-
mune to hepatitis A and B [previously vaccinated or with documented evidence of natural
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immunity] (group 1), and were attending for routine HIV follow-up (group 2) or community
HIV testing (group 3). Eligibility for the study for group 1 was determined by the reception
staff trained in study procedures by the study coordinator and was determined by the clinical
staff for groups 2 and 3.
Procedures
Eligible men in groups 1 who were seeking STI/HIV testing and group 2 who were seeking reg-
ular HIV care in person/contacting the clinic via telephone were offered a home sampling kit
(HSK) to obtain self-collected specimens for STI and HIV (group 1) and for STI (group 2) as
an alternative to routine testing in the GUM clinic. Group 3 men attending the community ser-
vice for HIV testing were offered a HSK, for STI only, if their rapid HIV test result was nega-
tive. Those opting for home self-sampling were given (or posted in case of group 1) an HSK
(Fig. 1) containing a urine pot, throat swab, rectal swab, oral fluid collection device (Orasure),
and a participant information sheet which had been developed with patients during an earlier
phase of the study [11]. Participants in Group 1 were asked to state on the specimen request
form if they wished to have a HIV test as part of their HSK screen. HSKs also contained a pre-
numbered questionnaire and an addressed envelope to return the study questionnaire to the
research team. All participants were asked to state their preferred method for receiving test re-
sults (telephone, letter, or email). Participants from all groups were asked to return the self-col-
lected specimens in person to the GUM or HIV clinic. In the event of non-return one reminder
to return the HSK was sent prior to the end of the study period using the participants preferred
method of contact specified in the request form. Treatment including partner notification was
performed according to standard clinic protocols. The clinic’s contemporaneous policy of ‘no
news is good news’ was followed in the context of negative results, unless participants had spe-
cifically requested otherwise.
Fig 1. Contents of the home sampling kits.
doi:10.1371/journal.pone.0120810.g001
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We maintained a prospective record of the total number of eligible men attending the study
sites during the study period. Data on the effect of HSK on STI testing rates during the historic
control period (the same calendar period as the study period in the previous year, i.e. February-
September 2007) for the HIV clinic cohort were extracted from the HIV clinic database which
includes data on STI screening, and self-reported STI testing rates in the community cohort
were extracted from the clinic records by the clinic staff. The clinic procedures for STI/HIV
testing were unchanged between study and historic control periods. HSK decliners in Group 1
completed a brief questionnaire about socio-demographics and preferences regarding STI test-
ing services and men in other groups were asked to give their reasons for declining a HSK.
Ethics Statement
This study including the consent procedures was approved by the Brighton East Research Eth-
ics Committee (Reference05/Q1907/127). Consent for study participation was implicit based
upon the patient choosing to use an HSK and its subsequent return. Thereby, formal written
informed consent at the time of recruitment was not obtained. As described previously, HIV
testing was performed only for those who had explicitly consented to be tested for HIV on the
specimen request form.
Specimen Collection and Analysis
All HSK specimens were analysed in the Sexually Transmitted Infection Bacterial Reference
Unit and Virus Reference Department at Public Health England, Colindale, London, UK.
Urine, rectal and pharyngeal swabs were tested for CT and Neisseria gonorrhoea (GC) using
the Aptima Combo 2 assay (AC2). Oral fluid specimen were tested for syphilis (ICE EIA) and
if applicable, for HIV antibodies employing an EIA method (GACELISA) [15]. Full details of
the testing methodology for CT and GC utilised in this study have been described elsewhere
[14].
Sample size and statistical methods
From our earlier work, which showed that approximately 80% of MSM accessing a GUM ser-
vice for STI testing would prefer a HSK to conventional testing [13], we estimated a require-
ment to recruit a minimum sample of 85 asymptomatic MSM attending the GUM clinic in
order to detect a difference in acceptability with 80% power and significance of 0.05. For the
HIV clinic attendees and for the community setting a minimum sample size of 260 and 140
were required respectively to detect a 10% increase in STI testing rates compared to rates in a
historical control period. In the same calendar period in the previous year the STI testing rates
were 17% in the community and 13% in the clinic.
The main study outcomes were: uptake of HSK compared to conventional clinic-based test-
ing for STI/HIV in group 1, increase in rates of STI testing due to availability of HSK in groups
2 and 3 compared to historical controls. HSK uptake and return rates between the 3 groups
were compared. HSK uptake and return rate for each study site was estimated as the proportion
of the total number of eligible participants who accepted a HSK and returned the specimens.
STATA v.10 was used for data management and analysis. One sample binomial test was con-
ducted to test the uptake of HSK compared to conventional testing in group 1. χ2 test was used
to compare STI testing uptake rates due to the availability of HSKs during the study period
compared to historical controls (groups 2 and 3), and HSK uptake and return rates between
the three groups.
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Results
Overall HSK uptake and return
A total of 574 eligible MSM were offered a HSK in the study period, of whom 433 (75%) ac-
cepted. The acceptance rates by testing site are given in Fig. 2. The uptake of HSK by study site
differed significantly (χ2 22.8; p<0.001). Uptake was highest amongst those attending the HIV
outpatient clinic (group 2; 81%), and was comparatively lower in the GUM clinic (group 1;
63%) and community based organisation (group 3; 66%). Overall, 47% (202/433) HSKs were
returned. Among those who had accepted an HSK, there was a significant difference in the re-
turn rate by study site (χ2 51.4; p<0.001). The return rate was highest amongst those attending
the GUM clinic (group 1; 78%), followed by HIV outpatient clinic (group 2; 44%), and lowest
amongst participants from the community based organisation (group 3; 16%).
Participant characteristics
Study questionnaires were returned by a high proportion of HSK users (92% GUM clinic, 84%
HIV outpatients and 100% of HSK users in the community). The median age of participants
was 42 years (IQR: 34–48), 87% were white British (Table 1). The majority of men self-identi-
fied as gay (98%), were educated beyond secondary school (87%) and 66% were employed. The
majority had been sexually active in the last 3 months (94%). Approximately 14% of men in
group 1 and 27% of men in group 2 reported engaging in unprotected insertive or receptive
anal sex in the last three months. Over a third (37%) had not tested for a STI in the last year.
Uptake of HSK compared to clinic-based testing
As hypothesised there was a greater acceptance of HSK (62.5% (95% CI: 53.5–70.9)) compared
to conventional GUM clinic-based testing (37.5% (95% CI: 29.1–46.5)) among men in group 1
Fig 2. HSK uptake and return in all the study sites.
doi:10.1371/journal.pone.0120810.g002
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(p = 0.0004). The uptake of HIV testing amongst these HSK users was 81% (n = 50/62) with
the median interval since last HIV test being 9 months (range: 1–186). There were no new HIV
diagnoses among MSM in group 1 (compared to one new diagnosis among men who opted for
conventional GUM clinic-based testing).
Impact of HSK on STI testing in HIV and community clinics
The overall STI testing rate in the MSMHIV outpatient clinic cohort increased from 13%
(139/1086) in the same calendar period in the previous year to 19% (220/1164; 131 from HSK
returners) during the study period (χ2 12.3; p<0.001). The STI testing rates in the MSM cohort
attending the community based organisation was unchanged between the two study periods,
17% (21 of 126) in the control period and 18% (15 out of 84) in the study period; 9 of whom
were HSK returners (χ2 1.665; p = 0.19).
Table 1. Socio-demographic profile, STI testing and sexual behaviour of HSK users (with returned questionnaires).
Factor GUM HIV Clinic Community Overall
Clinic Organisation
[%] [%] [%] [%]
N = 57 N = 110 N = 9 N = 176
Median Age [in years] [IQR] 33 [25–44] 44 [38–50] 41 [30–45] 42 [34–48]
Age Range [in years] 20–60 20–62 26–52 20–62
Age distribution
18–30 40.4 6.4 22.2 18.2
31–40 26.3 24.5 22.2 25.0
41–50 22.8 46.4 44.4 38.6
>50 10.5 22.7 11.1 18.2
Sexuality
Homosexual 96.5 99.0 100 98.3
Ethnicity
White British 84.2 88.0 88.9 86.9
Education [n = 171]
No formal education 1.8 8.6 0 5.8
A levels/GCSE/NVQ 49.1 50.5 44.4 49.7
Degree and above 45.6 30.5 55.6 36.8
Employment
Working 80.7 57.4 66.7 65.5
Tested for STI in last year
No 37.9 37.3 33.3 36.7
Had sex in last 3 months
Yes 98.3 92.3 78.0 93.5
Had unprotected insertive anal sex in the last 3 months
Yes 14.8 26.6 0.0 21.7
Had unprotected receptive anal sex in the last 3 months
Yes 13.0 30.0 0.0 23.4
doi:10.1371/journal.pone.0120810.t001
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Identification of STI
The overall STI prevalence in HSK returners was 13% (26/202). The prevalence was 9% (18/
202) for CT (13 rectal, 3 urethral, 2 pharyngeal), GC 2.5% (5/202; 3 pharyngeal, 1 urethral, 1
rectal), and 1.5% (3/202) for newly diagnosed syphilis (n = 3). Prevalence rates were similar for
each recruiting site: 13%, (8/62) for the GUM clinic (group 1), 13% (17/128) for the HIV clinic
(group 2), and 11% (1/9) for the community clinic (group 3).
HSK decliners: socio-demographic profile and STI testing behaviour
Based on data collected from 30 of the 48 (63%) decliners in the GUM clinic (group 1) we
found no significant differences between men who accepted or declined an HSK in age (median
33 years vs. 35; p = 0.75), STI testing in last year (62% vs. 62.5%; p = 1.00), willingness to wait
one day for a clinic appointment (8.6% vs. 8.3%; p = 0.93), or importance of accuracy of test re-
sults (95% vs. 98%; p = 0.95). Men in the HIV outpatient clinic declined an HSK because of
being in a monogamous relationship (13%), not being sexually active since last STI screen
(54%), and/or recent STI screen (40%). Men in the community based organisation surprisingly
expressed preference for conventional GUM clinic based STI testing (38%). The commonest
reason for declining an HSK in this group was that eligible subjects considered they did not
need an STI test (46%), this was either because they had tested for STI recently, or were in mo-
nogamous relationship but were testing for HIV because their partner was HIV positive.
Discussion
In this prospective observational study, we have demonstrated that overall the uptake of home
sampling was high amongst MSM attending the GUM and HIV outpatient clinics, and a com-
munity-based HIV testing service with acceptance by two-thirds of those offered although re-
turn rates varied and were highest among men who actively sought STI testing (group 1).
Given that HSKs were both acceptable and likely to be returned, HSK can be offered as a viable
alternative to GUM clinic based STI/HIV testing to asymptomatic MSM contacting GUM clin-
ics for an STI screen.
Home sampling for HIV was acceptable to most (81%) MSM in group 1. No new HIV diag-
noses were made which is not unexpected given the short duration of our study, and the sample
size of our study population. The high rate of acceptability of home self-sampling for HIV sug-
gests that HSK can be a viable method to increase the opportunities of HIV testing through di-
verse methods as emphasised in the National HIV testing policy and guidelines. Indeed, given
that HIV positive status was not a stated exclusion, some of the HIV test non-returners may al-
ready have been HIV positive and therefore the acceptability may be even higher than our fig-
ures suggest. No new HIV diagnoses were made which is not unexpected given the short
duration of our study, and the sample size of our study population.
Since the completion of this study, in the UK self-sampling HIV postal kits are being offered
by community based charitable organisations as well as GUM clinics. From April 2014 home
self-testing for HIV using point-of-care diagnostic tests has been legalised in the UK. Our
study data suggests that for MSM home sampling for HIV is likely to be acceptable; however
further evidence regarding the acceptability of home self-testing for HIV, and the effectiveness
of home sampling and home testing for HIV on reducing the burden of undiagnosed HIV and
increasing the frequency of HIV testing among at-risk MSM is needed.
In the non-GUM settings, although uptake of HSKs was high among MSM attending the
HIV outpatient clinic and community-based organisation, return rates were lower compared
to group 1. Nevertheless, a high proportion of HIV positive MSM who used the HSK for STI
testing had not tested for STI in the last year. When compared to the historical control period,
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during the study period the availability of HSK increased the proportion of HIV positive MSM
testing for STIs in the HIV outpatient clinic group 2. The Health Select Committee on HIV/
AIDS has emphasised the significance of STI control for HIV prevention [16]. National guide-
lines recommend an annual full sexual health screen for people living with HIV regardless of
their sexual history [17]. STI testing among HIV positive persons on antiretroviral treatment
(ART) is also vital for the success of ART for HIV prevention [18]. These data suggest that of-
fering HSK can enhance STI testing in this group. HSK for STI testing can especially be offered
in HIV outpatient clinics where STI testing service is not an integral part of HIV care and treat-
ment service. There was no change in the rate of STI testing observed among men attending
the community based organisation suggesting the need for further research to understand bar-
riers to and acceptable methods for STI testing among men accessing services in these settings.
The rates of STI detection amongst those sampling at home was high (13%) and similar to
rates seen in asymptomatic MSM attending the GUM clinic in the same time period with a
similar distribution of diagnoses of CT, GC and syphilis (8%, 4%, and 1% respectively). Given
this similar prevalence rate and the increased uptake of STI testing by the offer of HSKs, we
propose that novel strategies such as the offer of home sampling in addition to conventional
clinic-based testing is likely to facilitate the recognition of undiagnosed STIs which might oth-
erwise remain undiagnosed.
This is one of the first research studies to evaluate the use of home sampling for STIs and
HIV in MSM, a key group disproportionately affected by both STIs and HIV and specifically
targeted for novel testing strategies. Our findings are consistent with those of a subsequent
study [19] evaluating home sampling in MSM, in demonstrating high rates of acceptability and
STI diagnosis. Limitations of the study included the failure to reach the initial planned sample
size in the HIV clinic and community based organisation as the HSK return rate in these set-
tings was lower than originally anticipated. It appears that the return rates were much lower
when the primary aim of the encounter was not for an STI test but rather a routine outpatient
visit or specifically for HIV testing. This low return rate is consistent with that observed in
studies in heterosexual communities where home sampling kits are obtained outside the clini-
cal setting [20,21]. The requirement on individuals to return the completed kits in person may
have further exaggerated the low return rate we observed. Given that free home HIV sampling
kits can now be ordered online from some GUM clinics and community based organisations in
the UK, further research and service evaluation is needed to understand if offering postal deliv-
ery and return enhances HSK return rates. Since this was a prospective observational study and
not a randomised controlled study (randomising potential GUM clinic attenders to the offer of
an HSK or not) we are unable to conclude whether the availability of HSKs increase overall
rates of STI testing, but can conclude that the offer is acceptable to the majority of MSM seek-
ing STI tests. Also further research among those not returning HSKs is needed to understand
their reasons for not doing do. Secondly, the number of eligible subjects from the GUM clinic
was much lower than originally anticipated due to a combination of the requirement to be
asymptomatic, and the need to have a documented immunity to hepatitis A and B infections.
Future evaluation of home sampling should therefore include technologies for hepatitis virus
evaluation and should also include the testing of individuals symptomatic of STI if access to
conventional GUM services is not possible within a suitable time-frame. Thirdly, this study
was conceived at a time when access to GUM services was relatively poor. By the time the
study was implemented, a government target of 48-hour access to GUM services was in place
and so motivation for opting for home sampling may have been lower than
previously anticipated.
A further limitation is that this study was conducted in a single geographical area where up-
take of research in GUM/HIV clinics has been traditionally high. Therefore future studies
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should evaluate acceptability of HSK in other geographical areas. However, since the comple-
tion of the study, the routine offer of home sampling for HIV by some clinics throughout the
UK suggests this is unlikely to be a significant limitation.
This study serves as a “proof of concept” that home sampling for STI and HIV is acceptable
to a significant proportion of MSM and may therefore enable choice and broaden access to
testing for both STI and HIV in this target group. Future research should address the potential
impact of such increased access to testing on incidence rates of STI in this population and rates
of undiagnosed or late presentation of HIV infection. Indeed, a study conducted by Elliot and
colleagues has shown that offering home sampling for HIV to high-risk MSM via social net-
working websites is feasible and led to new HIV diagnosis [22]. The use of internet-based risk-
reduction advice and treatment [23] could be offered to HSK users to minimise the potentially
deleterious effects of reduced contact with clinical services. The optimal methods of kit design,
distribution, and handling should be further refined with evaluation of different sites for distri-
bution of HSK including a potential role for primary care services, pharmacies, and the inter-
net. The cost-effectiveness of offering HSKs for HIV and STI testing via different sites should
be assessed.
Conclusions
Home sampling for STI and HIV offers an alternative to conventional STI clinic attendance for
MSM seeking STI screening. It also significantly increases uptake of STI testing in HIV infected
MSM. Home self-sampling could therefore be considered as an adjunct to conventional clinical
services in order to improve STI/HIV testing outreach and uptake in this disproportionately
affected group.
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